Clinical Infectious Diseases: Open Access

ISSN: 2684-4559

Open Access

Effectiveness of VIUSID® and ASBRIP® in Hospitalized Patients Infected by SARS-CoV-2 and Mild-to-Moderate Respiratory Illness. An Observational Prospective Study


Wilson I Benites*, Martha V Heras, Mario L Mero and David Marquez

Background: The emerging SARS-CoV-2 infection has been associated with moderate and severe disease in patients with a weaker cellular immunity which might result in prolonged period of hospitalizations. Viusid® has shown recognized immunoregulator properties, including an important modulation on IFN-δ, TNF-α, IL-1β and IL-6 levels in patients with infectious diseases. Our observational study was aimed to evaluate the effectiveness of Viusid® along with Asbrip®, an upper respiratory antiseptic, in patients with mild to moderate symptoms related with SARS-COV-2 infection.

Methods: An observational study was conducted to evaluate the efficacy of Viusid and Asbrip® in patients with mild to moderate symptoms of respiratory disease caused by the emerging SARS-CoV-2 infection in 2019 at the Teodoro Maldonado Carbo University Hospital in Guayaquil, Ecuador. A total of 53 subjects were enrolled in our observational study. Of them, 44 were non-responders to the protocolized standard therapy for 46 ± 23 days. All of them received the protocolized standard therapy along with Viusid® 30 ml and Asbrip® 10 ml every 8 h for 21 days and assessed clinically until the hospital discharge.

Results: The results of the trial show that non-responders to the protocolized COVID-19 therapy patients taking Viusid® and Asbrip® experienced a significant improvement in their symptoms over a relatively shorter period of time. The average length of stay in the hospital with no changes was reduced once they were assigned to Viusid® and Asbrip® (15 ± 5 days). New hospitalizations were protocolized with the adjuvant therapy with an average length of stay in the hospital of 14 ± 6 days.

Conclusions: Viusid® in conjunction with Asbrip® might reduce the length of patient hospitalization in patients with SARS-COV-2 infection.


Share this article


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward